NCT05561374View on ClinicalTrials.gov

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 17, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

June 30, 2025

Conditions
High-grade GliomaOligodendrogliomaAstrocytomaGlioblastoma Multiforme
Interventions
DRUG

Low-dose OKN-007, BID

Participants will be administered low doses of oral OKN-007 two times a day daily in 28-day cycles.

DRUG

Low-dose OKN-007, TID

Participants will be administered low doses of oral OKN-007 three times a day daily in 28-day cycles.

DRUG

Mid-dose OKN-007, TID

Participants will be administered mid doses of oral OKN-007 three times a day daily in 28-day cycles.

DRUG

High-dose OKN-007, TID

Participants will be administered high doses of oral OKN-007 three times a day daily in 28-day cycles.

Trial Locations (4)

27157

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

40202

Norton Healthcare, Louisville

73104

The University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City

90404

Providence Saint John's Cancer Institute, Santa Monica

All Listed Sponsors
lead

Oblato, Inc.

INDUSTRY